Aurora Cannabis Gains EU Rights for Advanced Cannabis Strains, Strengthening Market Position

Aurora Cannabis Secures EU Community Plant Variety Rights for Innovative Genetics

Aurora Cannabis Inc., a prominent player in the global medical cannabis sector, has recently achieved a significant milestone by securing community plant variety rights from the EU's Community Plant Variety Office for two of its proprietary cannabis strains: Farm Gas™ (SOT20R07-007) and Sourdough™ (ACB21T044). This development underscores Aurora's commitment to advancing cannabis genetics and enhances its competitive edge in the burgeoning medical cannabis market. The awarded varieties, cultivated through sophisticated breeding and phenotyping methods at Aurora's Coast R&D facility in Canada, are characterized by their high potency, appealing aromas, and robust bud structure, which resonate well with medical patients across several countries, including Germany, Poland, the UK, Canada, and Australia.

The recognition from the EU not only affirms the scientific excellence achieved by Aurora's research teams but also provides the company with exclusive rights to the commercial production and sale of these cannabis varieties within the EU's 27 member states. This exclusivity paves the way for Aurora to capitalize on its investments in innovation, allowing for strategic expansion in one of the most rapidly evolving markets for medical cannabis. Lana Culley, Aurora's Vice President of Innovation and International Operations, emphasizes that this achievement highlights the superior cannabis genetics work undertaken by the company, positioning Aurora as a leader in the field.

With its robust genetics platform, Aurora strengthens its leadership in medical cannabis by ensuring the consistency and quality of its products. The ability to commercialize these cultivars not only in the EU but also in existing markets like Canada further cements Aurora's competitive stance. This advancement reflects the company's dedication to enhancing patient access to high-quality medical cannabis while reinforcing its status as a pioneer in the cannabis industry. As regulations continue to evolve, Aurora's focus on genetics and innovation promises to play a pivotal role in shaping the future of medical cannabis across various global markets.

In addition to this achievement, Aurora's focus on maintaining a diverse genetics portfolio is crucial for meeting the varied needs of medical patients worldwide. The company’s strategic investments in research and development ensure that it remains at the forefront of cannabis innovation, providing patients with reliable and effective treatment options.

As the medical cannabis landscape continues to expand, Aurora's commitment to scientific excellence and the cultivation of premium cannabis strains positions it well for sustained growth and leadership in the industry, ultimately fostering greater patient access and improving health outcomes globally.